Transgenomic Raising $7M in Sale of Convertible Preferred Shares | GenomeWeb

NEW YORK (GenomeWeb News) – Transgenomic today said that it expects to raise $7 million in gross proceeds from the sale of 1,443,297 convertible preferred shares.

The Omaha, Neb.-based molecular diagnostics company said that it will sell the shares of Series B convertible preferred shares to affiliates of investment firm Third Security at $4.85 per share. The preferred shares will be convertible into common shares of Transgenomic on a one-for-one basis, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.